Fresenius Kabi Recalls Morphine Sulfate Lot After Dilaudid Prefilled Syringe Labeling Mix-Up

A labeling failure at Fresenius Kabi has placed a potent opioid substitution error into the hands of distributors and healthcare facilities nationwide, raising immediate line clearance and label reconciliation questions for QA directors managing prefilled syringe operations. The company announced on August 4, 2026 a voluntary nationwide recall of one lot of Morphine Sulfate Injection USP, Simplist® 2 mg/1 mL after determining that MicroVault packaging labeled as morphine 2 mg/1 mL may contain a prefilled syringe of Dilaudid (hydromorphone HCl) 0.5 mg/0.5 mL.

The clinical risk profile is severe. Fresenius Kabi has acknowledged a reasonable probability of serious adverse health consequences, including life-threatening respiratory depression and death. Populations at elevated risk include opioid-naive patients, pediatric patients, individuals with underlying respiratory disease, and those concurrently receiving CNS depressants. No adverse events have been reported for the affected lot as of the recall announcement date.

Lot 11640282, with an expiration date of December 2028, was distributed nationally to wholesalers and distributors between January 29, 2026 and June 9, 2026 under NDC 76045-004-01 (unit of use) and 76045-004-11 (unit of sale). The recall is being conducted to the user level, meaning healthcare facilities holding affected stock are instructed to immediately cease distribution, dispensing, and use, and to arrange return through Inmar Rx Solutions.

For plant heads and QA leads, the root cause profile here is consistent with a label reconciliation breakdown or a line clearance failure during prefilled syringe assembly, two control points explicitly addressed under 21 CFR Part 211.122 (labeling issuance and use) and 21 CFR Part 211.130 (packaging and labeling operations). In a Simplist® format, where the outer MicroVault and the inner syringe are assembled as a unit-of-use system, any divergence between label stream and syringe fill identity represents a critical process control gap. ICH Q10 pharmaceutical quality system principles require that such mix-up risks be addressed through robust change control and process verification at every assembly stage.

Facilities that have not yet audited their own prefilled syringe label reconciliation procedures against current lot documentation should treat this recall as a direct prompt to do so, particularly where opioid products share a production line or staging area with other high-alert medications.

Fresenius Kabi's QA team is reachable at 1-866-716-2459 for recall-related inquiries; adverse events should be directed to 1-800-551-7176 or reported through FDA's MedWatch program.

The absence of adverse event reports at the time of announcement does not close the risk window, given the lot's distribution span of over four months and a 2028 expiration date that leaves affected units potentially in active inventory.

Source: FDA Recalls, Market Withdrawals & Safety Alerts via FDA.gov RSS Feed, August 5, 2026.